Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 30, 2008
AGI-1067 May Address More than the Blood Sugar
Analysis of: AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes | www.fiercebiotech.com
Author: GLG Expert Contributor
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 
May 28, 2008
Tekturna scripts
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
Author: GLG Expert Contributor
I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
May 19, 2008
What a bunch of horse crap.
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
Author: GLG Expert Contributor
 Study will be ridiculed.   1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.
May 14, 2008
Decreased DEXA reimbursement implications
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: GLG Expert Contributor
key implications: Less reimbursements for DEXA may lead to less testing, as cost of leasing equipment will be greater then revenue derived form procedures However, Less revenue/procedure could lead to greater utilization of equipment to cover costs involved and result in earlier testing of women...
April 9, 2008
PERISCOPE Makes Sense
Analysis of: New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes | pharmalive.com
Author: GLG Expert Contributor
The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression.  From...
April 9, 2008
Slim Chance?!
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Expert Contributor
Merck's endocannabinoid inverse agonist (CB1R )recently completed a 52 wk trial in which 2000 subjects were randomized to placebo, 2, 4, or 6 mg of taranabant.  Before the trial ended, the 6 mg dosed subjects had to be rerandomized to placebo or 4 mg due to toxicity.  The...
April 7, 2008
Taranabant Drections: To Success or to Failure?
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Expert Contributor
The article shows that Taranabant is promising anti-obesity drug that may have better luck with the FDA than Rimonabant. Although the trial results are excellent, the company removed higher doses from future trials! What we should learn from Rimonabant failure and Exenatide success?
April 7, 2008
Taranabant directions: To gain or to Failure
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Expert Contributor
The market is hungry for a weight loss drug with diabetes benefit. Currently, the FAD has phobia of the SEs with new drugs in this category Failure of Rimonabant was due to wrong direction of Sanofi Aventis in their approach to the FDA Taranabant may have better luck, especially if Merck take...
Joseph BassMarch 28, 2008
Another Glinide: Where's the Beef?
Analysis of: Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare
Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes.  With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel...
Carlos DujovneFebruary 19, 2008
China is the largest exporter of drugs or drug's ingredients and FDA does not have resources to check the quality of the majority of the imported as well as the USA produced generic drugs.
Analysis of: China Plant Played Role | online.wsj.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
1:Most of our legislators are forcefully endorsing generic drug usage and importing cheaper drugs.2:As a physician specialist in Clinical Pharmacologist I am fully aware or the safety and efficacy pitfalls of poorly manufactured  drugs and have done clinical research documenting the risks of patients...

Previous Page : 1 2 3 4 5 6 7 8 9 Next11 to 20 of 90

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773